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Abstract: Colorectal cancer (CRC) is the third most common cancer in the UK. The English 
National Health Service (NHS) Bowel Cancer Screening Program (BCSP) was introduced in 
2006 to improve CRC mortality by earlier detection of CRC. It is now offered to patients aged 
60–74 years and involves a home-based guaiac fecal occult blood test (gFOBt) biennially, and 
if positive, patients are offered a colonoscopy. This has been associated with a 15% reduction in 
mortality. In 2013, an additional arm to BCSP was introduced, Bowelscope. This offers patients 
aged 55 years a one-off flexible sigmoidoscopy, and if several adenomas are found, the patients 
are offered a completion colonoscopy. BCSP has been associated with a significant stage shift 
in CRC diagnosis; however, the uptake of bowel cancer screening remains lower than that for 
other screening programs. Further work is required to understand the reasons for nonparticipa-
tion of patients to ensure optimal uptake. A change of gFOBt kit to the fecal immunochemical 
tests (FIT) in the English BCSP may further increase patient participation. This, in addition 
to increased yield of neoplasia and cancers with the FIT kit, is likely to further improve CRC 
outcomes in the screened population.
Keywords: colorectal cancer, flexible sigmoidoscopy screening, Bowelscope, CT colongraphy, 
fecal immunochemical tests, gFOBt screening, uptake, quality in colonoscopy
Introduction
Colorectal cancer (CRC) is the third most common cancer diagnosis in the UK.1 Its 
incidence has risen by 5% in the past decade, and it is the second most common cancer 
death in the UK with a 5-year survival of 59%.1
The English National Health Service (NHS) Bowel Cancer Screening Program 
(BCSP) was introduced in 2006 to improve the outcomes and mortality of CRC by 
its earlier detection and thereby prevention of CRC. The program achieved full roll 
out in England and Wales in 2010. Eligible patients are invited to complete a home-
based guaiac fecal occult blood test (gFOBt) biennially. The test looks for tiny traces 
of blood. Typically, occult blood is detected in 2% of those who participate, and they 
are then followed up with a diagnostic test (most commonly colonoscopy).2 The NHS 
BCSP was initially targeted at those aged 60–69 years but the upper age limit was 
extended to 74 years in 2010. In the past 10 years, over 30 million people have been 
invited to participate in the BCSP.3 In addition, “Bowelscope” screening was intro-
duced in England in 2013. This involves a one-off flexible sigmoidoscopy at age 55 
years, with adenoma removal and completion colonoscopy for those with significant 
findings at flexible sigmoidoscopy. CRC screening in Scotland differs, in that biennial 
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screening is offered to those aged 50–74 years. At present, 
there is no Bowelscope screening in Scotland. In Wales and 
Northern Ireland, screening is similar to that in England in 
that gFOBt screening is offered to individuals aged 60–74 
years; however, there is currently no Bowelscope screening 
arm of the program. 
Organized CRC screening has been shown to detect 
CRC at an earlier stage, thereby improving morbidity and 
 mortality.2 The initial UK screening trial conducted in Not-
tingham offered biennial gFOBt, with colonoscopy where 
positive, to patients aged 45–74 years and demonstrated 
a 15% reduction in CRC mortality.4 Colonoscopy screen-
ing also gives the opportunity to detect adenomas, some 
of which are precursors to CRC, meaning that adenomas 
maybe removed thereby preventing development of CRC.5 
This paper reviews the NHS BCSP and discusses potential 
future direction.
Guaiac-based FOBt screening 
process
gFOBt population-based screening has been shown to 
improve CRC outcomes by reducing CRC mortality. Trials 
were conducted in Nottingham, UK; Funen, Denmark, and 
Minnesota, USA.4,6,7 The UK trial ran from 1985 and involved 
biennial screening utilizing non-rehydrated gFOBt in patients 
aged 50–74 years.4 Patients were followed up for a median of 
7.8 years (4.5–14.5 years), and individuals in the screening 
arm were offered gFOBt screening between 3 and 6 times.4 
In this study, 2.1% of gFOBt were positive, and its positive 
predictive values (PPVs) of neoplasia and cancer were 47.1% 
and 9.9%, respectively.4 Most importantly, the study demon-
strated a 15% reduction in CRC mortality through biennial 
gFOBT screening.4 The Danish trial methodology was similar 
to biennial screening, involving non-rehydrated gFOBt with 
10-year follow-up.6 Its main difference to the Nottingham 
study was that only responders during the initial round of 
screening were invited for subsequent rounds of screening. 
This study revealed a CRC reduction of 18%.6 The UK and 
Danish trials both revealed that nonresponders who were 
subsequently found to have CRC were commonly diagnosed 
with Dukes B, C, or D tumors. In the screened population, a 
stage shift was demonstrated, meaning that screen-detected 
cancers were more likely to be at an early stage (Dukes A 
or B).4,6 Furthermore, the mortality rate of screen-detected 
cancers was lower than that in the control group during 
follow-up.4,6 In contrast to these studies, the American trial 
used mostly rehydrated gFOBt testing, comparing annual 
and biennial screening and a control group (no screening).7 
Patients were followed up for 13 years. Annual screening was 
associated with 33% reduction in CRC mortality, whereas 
biennial screening reduced mortality by 6% (nonsignificant).7 
The reason for the disparity between annual screening and 
biennial screening is unclear.
The BCSP offers gFOBt screening to those aged 60 and 
74 years biennially. An invitation letter and information 
leaflet on bowel cancer and the BCSP are posted to patients, 
followed by a gFOBt kit. The kit contains six windows, in 
which patients are asked to fill with two fecal samples from 
three separate bowel motions. No dietary restrictions are 
required during the sampling period. Patients are asked to 
return the completed kit via freepost within a 14-day period 
from the initial bowel motion with a view to receiving a result 
letter within 2 weeks. Currently, in the UK, the gFOBt test kit 
is a non-rehydrated guaiac-based kit (Hema-screenTM). The 
test card is coated with guaiac, a reagent. Haem complexes 
contain pseudoperixodase, and when blood is present in 
stool, pseudoperoxidase in haem reacts with guaiac. When 
analyzed with hydrogen peroxide, this turns the sample blue. 
Early data from the NHS BCSP in 2013 demonstrated a 
gFOBt positivity rate of 2.08%, suggesting that a large pro-
portion of gFOBt tests are normal (no positive windows).8 
Where 1–4 windows are positive, this is regarded as a “weak 
positive,” and patients will require two completely negative 
repeat tests before discharge from that round of screening. 
However, if the repeat tests have any positive windows, 
patients proceed to a specialist screening practitioner (SSP) 
review to discuss colonoscopy. An abnormal gFOBt is 
regarded as ≥5 positive windows (out of 6). These patients 
proceed to review by SSP to discuss colonoscopy. In England, 
gFOBt kits are used throughout each stage of screening (until 
2018). However, in Scotland, Wales, and Northern Ireland, 
when a repeat test is required for a “weak positive” test, fecal 
immunochemical tests (FIT) kits are used. The two-tiered 
system involves retesting all positive gFOBt samples with 
the FIT kit. This is to prevent false-positive cases as the FIT 
kit is capable of detecting lower thresholds of blood present 
in stools. The differences between each kit are discussed in 
detail in “The future: FIT versus FOB” section. 
Within the English BCSP, patients who undergo polyp-
ectomy at colonoscopy are offered an SSP clinic appoint-
ment to discuss results and are offered ongoing adenoma 
surveillance based on the British Society of Gastroenterology 
(BSG) guidelines (Figure 1).9 Those diagnosed with CRC are 
referred to the local hospital multidisciplinary meeting for 
further investigation and ongoing treatment. Patients with a 
normal colonoscopy or low-risk polyps are discharged and 
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reinvited for further gFOBt testing as per BCSP. Patients 
with intermediate risk (at least one adenoma ≥1 cm in size 
or 3–4 small adenomas) or high-risk adenomas (more than 
three adenomas with one ≥1 cm in size or five or more 
small adenomas) at baseline colonoscopy are invited for a 
further colonoscopy for adenoma surveillance – high risk 
at 12 months and intermediate risk at 36 months.9 Patients 
on the adenoma surveillance programs are excluded from 
subsequent gFOBt rounds until adenoma surveillance is com-
plete. Patients with intermediate risk adenomas at baseline 
colonoscopy require two normal consecutive colonoscopies 
prior to discharge from the surveillance program, whereas 
those with high-risk adenomas require three consecutive 
normal colonoscopies.9 
Between 2009 and 2011, 90.6% of colonoscopies were 
performed following a “weak positive” gFOBt and 9.4% fol-
lowing an abnormal result.10 Of all colonoscopies performed, 
29.8% were normal and noncancerous findings were com-
mon (11.5%); most commonly, diverticular disease (33%), 
ulcerative colitis (15%), angiodysplasia (4.5%), Crohn’s 
disease (3.2%), rectal ulcer (2%), and radiation proctitis 
(1.8%).2 Within the first million returned gFOBt kits (2006 
to late 2008), CRC was identified in 10.1% of those with 
abnormal and weakly positive gFOBt and high-risk adenomas 
were identified in 9.8%.2 The PPVs for cancer and neoplasia 
of an abnormal gFOBt are 26% and 64.9%, respectively.11 
The risk of CRC was higher in those with abnormal gFOBt 
(21.3%–26%) compared to those with a “weak positive” 
result (5.9%–9%).10,11 Similarly, high-risk adenomas were 
more commonly seen in those with abnormal gFOBt (16%) 
compared to those with a “weak positive” result (10%).11 
The risk of CRC in a weakly positive gFOBt rose by 2.5% 
for every 10% rise in spot positivity (number of positive 
windows in each kit for one round of screening).10 Geraghty 
et al retrospectively observed patients diagnosed with cancer 
after two consecutive rounds of screening, finding that 90.6% 
had a normal gFOBt during the preceding round.10 It was 
also noted that patients with a combination of four positive 
spots in the first test kit but two normal subsequent kits had a 
similar risk of CRC to those who were offered colonoscopy.10
Figure 1 British Society of Gastroenterology guidelines for adenoma surveillance.
Note: Reproduced from Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002), Cairns et al, 59, 666–690, 2010 
with permission from BMJ Publishing Group Ltd.9
SURVEILLANCE FOLLOWING ADENOMA REMOVAL
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Table 1 shows the breakdown of CRC site depending on 
referral routes. Screen-detected CRCs were most commonly 
left-sided (74.2%), with 30% being rectal cancers, 6.3% in 
rectosigmoid, 31.7% in sigmoid, and 6.3% in the descending 
colon.12 This contrasts with the pattern of cancer distribution 
in the symptomatic population. Patients presenting through 
emergency admissions have more cecal cancers (34.4%) 
compared to sigmoid cancers (25.1%) or rectal cancers 
(14.0%).12 On the other hand, patients presenting through 
general practitioners (GPs) are more likely to have rectal 
cancers (35.4%), followed by cecal cancers (24.2%) and 
sigmoid cancers (21.8%).12 Overall screen-detected CRCs 
are more common in men (11.6%) than women (7.8%).8 
Rectal cancer is more common in men, whereas right-sided 
cancers are more common in women.2
The majority of bowel cancer cases present via GP refer-
rals (55%), followed by emergency presentations (20%) and 
bowel cancer screening (10%).12 Screen-detected cancers are 
often at an earlier stage compared to those diagnosed via GP 
referrals or presenting via emergency admissions.12 The lat-
ter groups were more likely to have advanced disease (nodal 
involvement or metastatic disease at presentation), with 
patients presenting via emergency admissions having more 
advanced disease compared to those referred in from GPs.12 
The first million returned FOBt kits suggest that 71.3% 
of cancers are at an early stage (polyp cancer 9.8%, Dukes A 
32%, Dukes B 29.5%).2 The remaining stages (Dukes C and 
D) were found in 25.7% and 3% of patients, respectively.2 
Comparing stage-matched screen-detected cancers to interval 
cancers (CRC detected in between rounds of screening, after 
a normal gFOBt or colonoscopy) and cancers identified in 
screening nonparticipants (patients who did not participate 
in gFOBt screening), the stage of cancer diagnosis favors 
patients in screening compared to the other groups. Dukes A 
cancers were found in 38.8% patients undergoing screening in 
comparison with 13.8%–18.8% in screening nonparticipants 
and interval cancers.13 Conversely, Dukes D cancers were far 
less common in screen-detected cancers (6.5%) compared 
to the latter groups (22.9%–23.2%).13 More importantly, 
patients with screen-detected cancers had better outcomes, 
with a superior 1-year survival (95.9%) compared to inter-
val cancers or screening nonparticipants (76.8%–78.4%).14 
Additionally, screen-detected Dukes C and D CRC patients 
had significantly better outcomes compared to interval can-
cers.13 Survival rates in those diagnosed out with the BCSP, 
including nonparticipants and interval cancers, were not 
significantly different between routes of diagnosis.15
Treatments received also varied among route of cancer 
diagnosis. Patients with screen-detected cancers were signifi-
cantly more likely to have curative treatment (88%) compared 
to those presenting via GPs (69%) or emergency admissions 
(52%).12 They were also more likely to receive major resec-
tions (79.3% vs 54.4%–62.7%) or local excisions (9.1% vs 
0.8%–3.5%) compared to the other routes of diagnosis.12 Of 
note, non-screen-detected cancers were more likely to not 
receive any treatment for bowel cancer compared to screen-
detected cancers (1.4%–4.9% vs 8%).12
Flexible sigmoidoscopy screening 
The adenoma–carcinoma pathway is the main pathway by 
which some adenomas transform into CRC over ~5–10 
years.16 Two thirds of colorectal neoplasia are detected in 
the sigmoid colon and rectum, and distal adenomas plateau 
at the age of 60 years.17 Adenomas over 1 cm and villous 
adenomas have higher malignant potential. 
The UK Flexible Sigmoidoscopy Screening Trial 
(UKFSST) included over 170,000 participants aged 55–64 
years across 14 centers, who were randomized into the control 
group or flexible sigmoidoscopy with adenoma clearance. 
Initially patients were followed up for a median of 11.2 years 
but have since been extended to 17 years.5 The initial CRC 
incidence and mortality reduction seen were sustained at 17 
years follow-up.5 In the intention-to-treat analysis (analysis 
based on all patients randomized to screening arm irrespective 
of attendance to screening), the incidence of all site CRC and 
distal CRC was reduced by 26% and 41%, respectively.5 In 
contrast, for per protocol analysis (analysis based on patients 
in screening arm who attended for flexible sigmoidoscopy), 
the reduction of CRC incidence was greater, with all-site 
CRC and distal CRC incidence reduced by 35% and 56%, 
respectively.5 There was no significant effect on proximal 
CRC incidence in either the intention-to-treat analysis or per 
protocol analysis.5 Mortality reduction occurred in 30% for 
Table 1 Breakdown of CRC site based on referral route
Site/referral 
route
Screening (%) Emergency  
admission (%)
GP  
referral (%)
Rectal 30 14.0 35.4
Rectosigmoid 6.3 4.2 5.5
Sigmoid colon 31.7 25.1 21.8
Splenic flexure/
descending colon
6.2 9.4 4.7
Transverse colon 5.7 8.2 5.0
Hepatic flexure 3.4 4.8 3.4
Cecum/ascending 
colon
16.9 34.4 24.2
Note: Data from Braun et al.12
Abbreviations: CRC, colorectal cancer; GP, general practitioner.
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all-site CRC, and 46% for distal CRC in the intention-to-
treat analysis, but was 41% and 66%, respectively, in the per 
protocol analysis.5 Proximal CRC mortality reduction was not 
statistically significant on either analysis. The reduction of 
CRC incidence and mortality was greater at 17 years follow-
up compared to that at the initial follow-up at the median of 
11.2 years. 
The findings were similar in the Italian SCORE trial with 
the same study protocol as the UKFSST trial, with all-site 
CRC reduction of 18% (24% for distal CRC).18 Mortality was 
reduced by 22%, but this was nonsignificant in intention-to-
treat analyses.18 A US trial demonstrated reductions in CRC 
incidence by 21% and overall mortality by 26%.19 In particu-
lar, distal cancer incidence was reduced by 29%, associated 
with a mortality reduction of 50%.19 This trial differed from 
the UKFSST and SCORE trials in that patients included 
were aged 55–74 years and received a further screening sig-
moidoscopy at either a 3- or 5-year interval.19 The US trial 
found that risk reduction was similar for those aged 55–64 
years and 65–74 years.19 The NORCCAP study in Norway 
randomized participants to flexible sigmoidoscopy or flexible 
sigmoidoscopy in combination with FOBt and revealed no 
difference in incidence of CRC at 7 years; however, CRC 
incidence was reduced by 20% and mortality by 27% after 
11 years of follow-up.20 The addition of a one-off FOBt did 
not increase CRC or adenoma detection.20 Divergence of 
mortality between screening and control group occurred 
after 9 years.20 
The UKFSST trial found that to prevent one case of 
CRC, 191 patients needed to be screened at the 11 years 
follow-up.21 This number reduced to 98 at the 17 years 
follow-up.5 The American PLCO trial found that this was 
higher at 282.19
A significant advantage of flexible sigmoidoscopy as a 
screening investigation is the ability to do the test without 
full bowel preparation. There are concerns, however, that 
proximal pathology may be missed, but the UKFSST trial 
did not reveal a difference in incidence of proximal cancers 
in the intervention or control group.21 The SCORE trial 
detected a 9% reduction in proximal CRC, whereas the 
PLCO trial had a 29% reduction in proximal CRC with 
screening.18,19 
An unexpected finding from the UKFSST trial was that 
after the first 4 years of expected increase in CRC incidence 
in the intervention group, incidence in the control group rose 
steadily compared to the intervention arm.21 The SCORE 
trial findings were similar, but differed in that the crossover 
was seen at 5 years.18 This reaffirms the use of Bowelscope 
 screening in addition to gFOBt testing in maximizing poten-
tial of CRC incidence and mortality reduction.
Flexible sigmoidoscopy screening has improved mortality 
for each stage of cancer, more so for more advanced stages 
of disease.19 The American trial demonstrated that for distal 
CRC, mortality was reduced by 21.4% for stage I cancers 
and by 60.7% for stage IV cancers.19
Bowelscope screening was introduced into the BCSP in 
2013, with plans for full roll out in England by 2018. It is a 
one-off flexible sigmoidoscopy offered to individuals aged 
55 years, with an aim to reduce CRC incidence by identify-
ing and removing pre-cancerous adenomas. Individuals aged 
over 55 years may self-refer for the test up to the age of 60 
years, at which point they enter the gFOBt BCSP. Eligible 
patients are sent an initial invite, with a subsequent appoint-
ment invitation and information leaflet. Patients with high-
risk features proceed to completion colonoscopy, that is, ≥3 
adenomas, single adenoma ≥10 mm, tubulovillous adenoma, 
or ≥20 hyperplastic appearing polyps above the distal rectum.
Uptake 
The benefits of screening programs are maximized with 
higher uptake. Overall, the uptake of BCSP (gFOBt and 
Bowelscope) is less than other national screening programs 
such as breast cancer or cervical cancer where the uptake of 
these were above 72% each in 2015/2016.22,23 Familiarity and 
acceptability of the screening program may well play a part. 
gFOBt screening
The initial UK pilot study for gFOBt screening (1985–1991) 
had an uptake of 56.8%.24 This is similar to the current 
program uptake of gFOBt screening of 57.9% between 
2012–2015.25 A recent UK study showed that the majority 
of patients with an abnormal gFOBt attended an SSP clinic 
(94%), and 83% subsequently attended for investigation.8 
Overall, uptake of colonoscopy following positive gFOBt 
is 79%.2
Data so far suggest that nonresponders of gFOBt screen-
ing are more likely to be younger, male, of an ethnically 
diverse background, or of more deprived socioeconomic 
status.2 Uptake was 4.8% higher in women compared to 
men.2 Variation of uptake between UK regions also exists, 
with uptake for all quintiles of deprivation including those 
who are in the least deprived areas are higher in the North 
East compared to other regions in the UK.2 
The unpleasantness associated with obtaining multiple stool 
samples is a common reason for nonresponding. Other reasons 
include poor understanding of CRC risk, low health literacy, 
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perceptions that screening is not required, that their GP will be 
consulted if they become symptomatic, or anxiety of possible 
positive result.26 When interviewed on reasons for nonrespond-
ing, some individuals had not decided on participation, whereas 
some had yet to submit the FOB kit due to other priorities.26 
A face-to-face survey of participants of BCSP screen-
ing revealed that only 52% of survey participants have read 
almost all of the “Bowel Cancer Screening: The Facts” 
booklet, whereas 22% had read none of it.27 Furthermore, 
31% of survey participants never participated in BCSP, and 
of these participants, 63% never read the booklet.27 This 
suggest that other means of communication with patients 
who never intended to participate in BCSP is required other 
than the facts booklet. This may be related to poor health 
literacy in these individuals. The ASCEND trial assessed four 
interventions to narrow down the socioeconomic gradient in 
screening participation, namely, additional supplementary 
leaflet containing a summary of key information, a narrative 
of participant’s stories, a general practice endorsement of the 
BCSP, and an enhanced reminder letter.28 Sending additional 
leaflets had no effect on uptake.28 Only the enhanced reminder 
letter that contained a banner with the words “A reminder for 
you” at the beginning of it followed up with a brief motiva-
tional message reduced the socioeconomic gradient in uptake, 
while GP endorsement significantly increased uptake but did 
not reduce the socioeconomic gradient.28 A recent trial of text 
message reminders found no significant main effect but a 
significant 5% increase in uptake among first-time invitees.29
Bowelscope screening
Uptake of Bowelscope screening is lower than that of gFOBT 
screening. In the UKFSST, only 53% of potentially eligible 
people responded that they would take up the offer of screen-
ing when a questionnaire assessing interest in participation 
was sent.21 In the trial, 71% of those who had been random-
ized into the intervention group attended screening.21 Sub-
sequent feasibility studies of screening reported uptake to be 
45%–55%.30,31 At 14 months after Bowelscope introduction, 
the uptake in the pilot centers was 43.1%.32 
Men were more likely to attend than women (44.6% vs 
41.5%), and those in least deprived areas were more likely 
to participate than those in most deprived areas (53.2% vs 
32.7%).32 Appointment slots also had an impact on screening 
participation. Those who had been offered an appointment 
out of hours (weekday evenings, Saturday mornings, and 
afternoons) were more likely to attend than those offered 
a weekday appointment, but this was nonsignificant in the 
multivariate analysis.32 
Individuals may decline to attend screening due to the 
invasive nature and lack of understanding of flexible sigmoid-
oscopy. Furthermore, the unfamiliarity of using an enema 
prior to the test may contribute to this. Other reasons include 
competing interests, being unable to attend the scheduled 
appointment, fear of possible endoscopy findings or com-
plications, unwillingness to administer enema, anticipated 
discomfort, or that participating would waste health care 
resources.33 When screening attenders and nonattenders were 
interviewed, no interviewees cited the ability of the screening 
tool to prevent cancer by removing potentially precancerous 
polyps, suggesting that colorectal polyps are not something 
that the general public associate with malignancy.33 
Robb et al evaluated patient response to initial and 
subsequent reminder invitation in Bowelscope screening. It 
was found that the proportion of patients responding to the 
invitation (either accepting, declining, or re-arranging the 
appointment) were similar (27%–30%) during the initial or 
first and second reminder invites.31 In another study, when 
nonresponders were re-invited with a reminder at 12 months, 
of those who self-referred back for an appointment, 90% of 
these individuals (67% men and 100% women) requested for 
same-gender practitioner.34 Unlike breast cancer and cervical 
cancer screening which are gender specific, the practitioner 
who delivers these screening modalities are more likely to 
be female. It is not current standard practice in the UK to 
have same gender practitioner endoscopy lists. Patients may 
be uncomfortable about the possibility of opposite gender 
practitioner and decline to participate. This may deter patient 
participation. For patients in gFOBt screening, this may be 
addressed during consultation with SSP, but for Bowelscope 
patients, there is no similar avenue to discuss this. A feasibil-
ity study is currently underway evaluating the use of SSPs to 
increase the uptake in Bowelscope screening.35
Quality of endoscopy 
All BCSP colonoscopies are carried out at Joint Advisory 
Group (JAG)-accredited screening centers by screening-
accredited colonoscopists. Accreditation for BCSP requires 
a lifetime experience of over 1000 colonoscopies, cecal 
intubation rate above 90%, and adenoma detection rate 
(ADR) of over 20% in the preceding 12 months. All BCSP 
screeners undergo an accreditation examination and have 
regular ongoing quality assurance measurements against 
these benchmark indicators. 
BCSP delivers a high standard of colonoscopy.36 All colo-
noscopies performed within the BCSP are recorded in the 
BCSP database, which has provided a wealth of information 
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for research into CRC screening and colonoscopy standards. 
Through this, several quality indicators have been studied 
including ADR, polyp detection rate, colonoscopy withdrawal 
time (CWT), cecal intubation rate, rectal retroversion rate, 
polyp retrieval rate, sedation practice, bowel preparation 
scores, and adverse events.37,38
The aim of these standards is to reduce variation. Intuba-
tion rate of >90% is a desired target for colonoscopy, with 
adequate bowel preparation enabling sufficient adequate 
diagnostic quality in ≥90% of cases. ADR is used as a sur-
rogate marker for thorough colonic examination. It is widely 
accepted that improving ADR has a beneficial effect in 
improving CRC incidence and mortality, but it has also been 
associated with reducing interval CRC.39 ADR of >15% has 
been defined as the minimum standard in the symptomatic 
population; however, ADR in BCSP examinations should 
exceed 35%.40 
Mean CWT in the BCSP is 8.4 minutes.41 BCSP data 
suggest that withdrawal time of >6 minutes is associated with 
increased ADR, in particular right-sided lesions.42 Lee et al 
found that the optimal CWT was 10 minutes as this allows 
for greater attention to deeper folds, difficult corners, and 
aspiration of pools of fluid.43 CWT above this time did not 
improve ADR further. 
The use of anti-spasmodic therapy such as buscopan has 
been evaluated in improving ADR. Within the BCSP, busco-
pan use is associated with a 30% higher ADR and is routinely 
recommended where there are no contraindications.42 This 
has not been replicated in meta-analysis of RCTs.44 Other 
areas such as digital rectal examination and rectal retroflex-
ion have also been recommended as they may increase the 
detection of rectal adenomas. 
Good sedation practice is essential to minimize 
medication- related complications. Table 2 shows the cur-
rent recommendation for use of pethidine, fentanyl, and 
midazolam in different age groups from JAG and BSG.45 
Sedation practice within the BCSP has been shown to be 
comparable to these recommendations.8
Alongside these quality indicators, patient comfort 
and experience are essential within screening programs 
and to ensure patient reattendance. In the BCSP, the mean 
 colonoscopy procedure time was 26.2 minutes.41 Data suggest 
that most cases in BCSP are well tolerated, with 91.1% of 
cases rated as no discomfort or mild or minimal discomfort.46 
Cases with moderate or severe discomfort (8.9%) were asso-
ciated with longer insertion and withdrawal times.46 Cases 
with significant discomfort had similar ADRs to cases where 
the colonoscopy was well tolerated. There was no associa-
tion between the use of sedation or analgesia and significant 
discomfort.46
Colonoscopy carries a small risk of adverse events and 
complications, namely, bleeding and perforation. The risk 
of these occurring is small in diagnostic procedures and 
increases with the use of therapy. The most common adverse 
event reported was bleeding post-polypectomy (42 cases), fol-
lowed by colonic perforation (12 cases).2 The risk of bleeding 
was found to be at 0.26% and colonic perforation of 0.04%.37
Quality assurance also extends to Bowelscope screening. 
The benchmark ADR in Bowelscope is 12.1% based on the 
UKFSST.47 Bowelscope pilot data (2013/2014) revealed an 
average ADR of 9.2%.48 The difference in ADR between these 
studies could be related to different age groups recruited 
(UKFSST – age 55–64 years; Bowelscope – age 55 years 
only). Furthermore, Bowelscope screening is an open invita-
tion to everyone aged 55 years and reflects real-world data, 
whereas the UKFSST study population were self-selecting in 
that they registered interest in participation. Both the studies 
found significant variation of ADR between endoscopists. 
This was not accounted for by adjusting confounding factors 
and was due to difference in performance among endosco-
pists.47 The Bowelscope pilot identified that adenomas were 
more commonly detected in males (11.5%) than females 
(6.7%), and gender-adjusted ADR has been suggested to 
assess an endoscopist performance.48 Further review of this 
when Bowelscope is fully rolled out would help to evaluate 
this further. 
CT colonography (CTC) compared 
to colonoscopy
Patients with abnormal gFOBt or flexible sigmoidoscopy 
with high-risk features in Bowelscope screening are invited 
for review with SSP to discuss colonoscopy. Occasionally, 
patients are deemed unfit for this (<3%).2 Most patients 
underwent a colonoscopy (97%), followed by CTC (2%), 
plain CT abdomen (0.4%), and barium enema (0.3%).8 
Although commonly perceived as less invasive, CTC still 
requires bowel preparation, although the volume of ingestion 
is much less. This could either be in the form of picolax or 
gastrograffin which also has dual function for fecal tagging. 
Table 2 Current recommended sedation practice
<70 years >70 years
Pethidine ≤50 mg ≤25 mg
Fentanyl ≤100 µg ≤50 µg
Midazolam ≤5 mg ≤2 mg
Note: Data from British Society of Gastroenterology.45
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CTC requires rectal probe insertion for aiding bowel disten-
sion with either room air or carbon dioxide. Furthermore, 
CTC requires movement between prone and supine positions. 
In the nonscreening population, CTC is a reasonable 
alternative to colonoscopy in patients deemed unfit for colo-
noscopy. European Society of Gastrointestinal Endoscopy 
(ESGE) guidance suggests that CTC is recommended over 
barium enema for the diagnosis of colorectal neoplasia.49 
A meta-analysis of CTC suggests that it has a sensitivity 
of 96% in identifying CRC and polyps in symptomatic and 
screening patients.50 The SIGGAR trial (a multicentered, 
randomized control trial) evaluated CTC in comparison 
with colonoscopy in the symptomatic cohort and identified 
that CTC is comparable to colonoscopy in identification of 
cancers or polyps above 1 cm where the pickup rate was 11% 
on both the arms.51
Complications with CTC are rare (0.5%).52 The most 
significant complication associated with CTC is colonic 
perforation which may occur during active diverticulitis or 
acute colitis in patients undergoing CTC. A meta-analysis 
revealed that CTC-related colonic perforation was low at 
0.01%.53 Radiation exposure is an often-cited consideration 
when considering CTC over colonoscopy; however, the 
radiation risk associated with a single CTC is low. A study 
reported that the lifetime risk of cancer is increased by 0.2% 
when undergoing screening every 5 years between the ages of 
50 and 80 years.54 Additionally, CTC may also pick up extra-
colonic findings. These findings may include new diagnosis 
of non-CRC cancer or other significant noncancer findings 
such as abdominal aortic aneurysm or adrenal masses. In 
the SIGGAR trial, in patients randomized to the CTC arm, 
30% of patients were referred for endoscopic evaluation for 
suspected malignancy, polyps, or uncertainty on imaging, 
whereas 10% were referred for the evaluation of extracolonic 
findings.51 Whether utilizing CTC as a first-line investigation 
is cost-effective due to the need for subsequent investigations 
from incidental findings which may not be clinically relevant 
is not yet known. 
Although reassuringly safe, the use of CTC in the setting 
of bowel cancer screening is still being evaluated. Plumb et 
al55 reviewed CTC as a first-line investigation in patients with 
subsequent endoscopic investigations through the BCSP data-
base. The authors found that detection of cancers, advanced 
neoplasia, or large polyps >1 cm in size was superior in 
colonoscopy (9.0%, 32.7%, 20.6%, respectively) compared 
to CTC (4.5%, 18.5%, 12.4%, respectively).55 Of note, this 
study revealed variation in the detection rates for abnor-
malities depending on centers, suggesting that experience of 
radiologists in BCSP may account partly for these findings. 
Additionally, a meta-analysis in the screening population of 
patients with a positive FOBt who underwent a CTC found 
that CTC is 89% sensitive and 75% specific for adenomas 
≥6 mm.56 There is an increasing understanding and research 
into the use of bowel preparation and fecal tagging in CTC as 
well as increasing training in the interpretation of CT imag-
ing, and this may contribute to further improvement in the 
quality of CTCs and its interpretation in the future. ESGE 
currently recommends CTC for patients unfit for colonoscopy 
or patients who have had an incomplete colonoscopy.49 How-
ever, at present, there is insufficient evidence to support CTC 
as a first-line investigation in patients with positive gFOBt.49
Patient experience 
Patient experience is an increasingly important marker of 
care quality and forms part of the UK Government’s com-
mitment to health policy and service improvement.57,58 A 
recent inquiry into an NHS Trust with high mortality rates 
described how loss of sight of patients at the center of health 
care adversely affected clinical quality.59 Ensuring positive 
patient experience is crucial to ensure maximal screening pro-
gram participation, in addition to ensuring repeat attendance 
for surveillance procedures.60,61 Although the link between 
patient experience and colonoscopy outcomes has not been 
fully explored, it is likely that endoscopists who provide 
a better patient experience are more likely to offer higher 
quality endoscopy.62 At present, patient experience within the 
BCSP is measured using a nurse/clinician-derived satisfac-
tion questionnaire, meaning that the items assessed have been 
devised by health care professionals without patient input. 
A future challenge for the BCSP will be to incorporate truly 
patient-reported experience measures to enable assessment 
of patient experience according to patient-derived priorities.63
Patient-reported satisfaction of NHS BCSP colonoscopy 
is generally positive. More than 95% of patients felt that 
they understood the risks and benefits of the procedure, and 
>98% of patients felt respected and that their privacy was 
maintained during the hospital visit.64 About 20% of patients 
felt that colonoscopy was more uncomfortable than antici-
pated, and about 5% of patients asked for the colonoscopy to 
be stopped.64 Around 12.8%–16.9% of patients experienced 
abdominal pain post colonoscopy.64 In contrast, in patients 
who underwent CTC, 25.7% felt it was more uncomfortable 
than expected, as opposed to 21% of patients who under-
went colonoscopy.52 There was no significant difference in 
unexpected discomfort between procedures among patients 
who underwent colonoscopy following an abnormal CTC.52 
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Conversely, a higher proportion of patients found colonos-
copy unexpectedly more uncomfortable following incomplete 
CTC (57%) than the CTC itself (26.3%).52 Anorectal pain and 
abdominal pain were most commonly reported, the cause for 
this being likely multifactorial, including colonoscopy tech-
nique and patient-related factors such as previous abdominal 
surgery and poor patient tolerance. 
The difference in perceptions of comfort for the investiga-
tion modality may vary due to patient expectations or from 
lack of counseling prior to either investigation. As CTC may 
be perceived as more comfortable compared to colonos-
copy, this may account for the higher levels of unexpected 
discomfort for patients receiving CTC first line. Overall, 
from a patient comfort point of view, CTC has been found 
to be acceptable and comparable to colonoscopy in terms of 
comfort; however, further work is required to compare the 
overall patient experience of each modality.
The future: FIT versus FOB
gFOBt has been used since the commencement of BCSP. 
Other screening programs in France, Italy, Spain, and Nor-
way use FIT. There are two different versions of FIT kits; 
one is qualitative and the other quantitative. The former 
requires a visual interpretation of results, giving rise to the 
possibility of inter-observer variation. The latter measures 
the actual fecal hemoglobin concentration. Different kits 
are available for these two subtypes, and each varies in 
performance, and therefore, each kit must be considered 
individually. 
One main difference between gFOBt and FIT is the 
sampling method and number of stool samples collected. 
Only one fecal sample collection is required for FIT. Fecal 
sampling also varies in that the sampling stick is re-inserted 
into the collector as opposed to smeared onto the test card 
as in gFOBt. With gFOBt, only stool that has not yet been 
in the toilet bowl is collected. The sampling method and the 
collection of only one sample may improve the acceptability 
of gFOBt for nonresponders. In the UK FIT national screen-
ing pilot, uptake in patients randomized to the FIT group was 
higher than gFOBt (66.4% vs 59.3%).65 More importantly, 
the uptake of FIT screening test was doubled in previous 
nonresponders.65 Changing from gFOBt to FIT may improve 
participation of patients in BCSP. In this trial, uptake of 
colonoscopy irrespective of the stool test kit was similar.65
The main difference between the two kits is the detec-
tion level of fecal blood concentration. gFOBt kit can detect 
fecal blood concentration of 0.6 mg Hb/g, whereas FIT 
can detect a much lower concentration of 0.02 mg Hb/g. 
This large difference in the detection levels has led many to 
believe that FIT is superior. gFOBt is not specific for colonic 
human blood; it can also be positive in response to muscle 
protein, gastrointestinal irritation due to medication or upper 
gastrointestinal bleeding, whereas FIT is specific for human 
colonic bleeding.10 The PPV of FIT was greater than that 
of gFOBt for advanced adenoma (1.73% vs 0.35%) and all 
neoplasia (3.74% vs 0.76%).65 A meta-analysis identified 
that FIT has a sensitivity and specificity of 79% and 94%, 
respectively.66 Additionally, it detects twice more CRCs and 
advanced adenomas.65 Implementation of FIT has also been 
shown to reduce CRC incidence by 10%.67
In the FIT screening pilot in England, a quantitative FIT 
kit was used. Various cutoff levels of FIT and its detection rate 
of neoplasia were evaluated against gFOBt. Using a cutoff 
of 0.02 mg Hb/g, FIT was better at detecting CRC (0.27% 
vs 0.12%) and adenoma (1.73% vs 0.35%).65 Lowering the 
FIT cutoff value may increase the PPV for CRC and ADR; 
however, this would need to be balanced against the likely 
resulting increased demand for colonoscopy which could 
exceed the capacity of BCSP units. The authors felt that with 
a FIT cutoff of 0.18 mg Hb/g, the numbers of colonoscopy 
generated were comparable to the gFOBt arm, but would 
increase the yield of CRCs and adenomas.65
As of June 2016, it has been announced that FIT kit will 
be rolled out in 2018 to replace gFOBt nationally in England. 
Conclusion
BCSP has been running in England for the past 11 years, 
and it has been 4 years since Bowelscope was introduced 
alongside gFOBt screening. A significant stage shift has 
been observed. The addition of Bowelscope screening will 
likely reduce CRC incidence and improve mortality further. 
However, uptake of bowel cancer screening remains below 
that of other screening programs, and work to improve 
palatability and uptake of screening is required. Changing 
to FIT may further enhance BCSP in terms of anticipated 
increased participation and increased yield of CRC or neo-
plasia. Areas requiring further research to improve on CRC 
outcomes could potentially include interval cancers and 
uptake in previous nonresponders. As the BCSP database 
provides a wealth of information for research, this will 
aid further research into bowel cancer screening. Overall, 
the future of BCSP with a change to FIT and addition of 
Bowelscope is likely to see further improvements in CRC 
morbidity and mortality.
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